Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Lululemon (LULU) Tops Q4 Earnings and Revenue Estimates
Lululemon (LULU) Tops Q4 Earnings and Revenue Estimates

Lululemon (LULU) came out with quarterly earnings of $5.01 per share, beating the Zacks Consensus Estimate of $4.76 per share. This compares to earnings of $6.14 per share a year ago. These figures

Energy Vault Holdings, Inc. (NRGV) Reports Q4 Loss, Tops Revenue Estimates
Energy Vault Holdings, Inc. (NRGV) Reports Q4 Loss, Tops Revenue Estimates

Energy Vault Holdings, Inc. (NRGV) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.35 per share a year ago

DocuSign (DOCU) Beats Q4 Earnings and Revenue Estimates
DocuSign (DOCU) Beats Q4 Earnings and Revenue Estimates

DocuSign (DOCU) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.86 per share a year ago. These figures

HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates
HealthEquity (HQY) Beats Q4 Earnings and Revenue Estimates

HealthEquity (HQY) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.69 per share a year ago. These

Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.15 per share a year ago. These figures are

Why Credo and Astera Soared After Oracle and Broadcom's Earnings
Why Credo and Astera Soared After Oracle and Broadcom's Earnings

Credo Technology (NASDAQ: CRDO) and Astera Labs (NASDAQ: ALAB) are some of the fastest-growing beneficiaries of the artificial intelligence (AI) data center buildout.

As key suppliers in the data

Micron Continues to Display The Power of the Zacks Rank
Micron Continues to Display The Power of the Zacks Rank

Micron MU is a world leader in innovative memory and storage solutions that accelerate the transformation of information into intelligence. Shares have been red hot on the back of the AI frenzy

NVIDIA Rally? The Market Hasn’t Seen Anything Yet
NVIDIA Rally? The Market Hasn’t Seen Anything Yet

If you think that NVIDIA’s (NASDAQ: NVDA) rally-to-date has been impressive, just wait for what comes next. News revealed at the GTC developer conference shows the AI boom is still growing, much

Top Stock Reports for GE Aerospace, Shell & McKesson
Top Stock Reports for GE Aerospace, Shell & McKesson

Tuesday, March 17, 2026The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including GE Aerospace

Rubrik’s Selloff Could Be Cybersecurity’s Hidden Opportunity
Rubrik’s Selloff Could Be Cybersecurity’s Hidden Opportunity

Rubrik (NYSE: RBRK) is a different kind of cybersecurity company, generating impressive growth as customers recognize the value of its differentiated approach. Most cybersecurity companies focus

Howmet's Defense Aerospace Strength Seems Firm: More Upside Ahead?
Howmet's Defense Aerospace Strength Seems Firm: More Upside Ahead?

Howmet Aerospace Inc. HWM is poised to gain from the expanding defense budget, which remains a key growth catalyst. In the fourth quarter of 2025, revenues from the defense aerospace market rose 20%

CSCO Taps NVIDIA to Drive Secure AI at the Edge: More Upside Ahead?
CSCO Taps NVIDIA to Drive Secure AI at the Edge: More Upside Ahead?

Cisco Systems CSCO is expanding its Secure AI Factory with NVIDIA Corporation (NVDA), which will enable enterprises to run AI everywhere instead of only in large data centers. The expanded solution

AIG Expands Specialty Reach With McGill Tie-Up, Targets $1.6B Book
AIG Expands Specialty Reach With McGill Tie-Up, Targets $1.6B Book

American International Group, Inc. AIG recently entered into a long-term strategic partnership with McGill and Partners. The goal is to modernize specialty insurance using data and digital tools

Best Value Stocks to Buy Now and How to Find Them
Best Value Stocks to Buy Now and How to Find Them

No one knows what’s right around the corner given the geopolitical turmoil. Still, stocks jumped slightly through morning trading on Tuesday after the Nasdaq and the S&P 500 charged higher to start

Palantir’s New Partnership Continues Separating Fact From Fiction
Palantir’s New Partnership Continues Separating Fact From Fiction

There are several headlines that are taking a backseat to more pressing geopolitical concerns. However, the announcement that Palantir Technologies (NASDAQ: PLTR) and NVIDIA (NASDAQ: NVDA) are

2 Top Performing Stocks to Watch as Earnings Approach: FIVE, MU
2 Top Performing Stocks to Watch as Earnings Approach: FIVE, MU

Set to release their quarterly reports after-market hours on Wednesday, March 18, Five Below FIVE and Micron Technology MU are two of the hottest stocks to consider at the moment. 

Providing quality

The New Threat IBM's Quantum Computing Research Poses to D-Wave
The New Threat IBM's Quantum Computing Research Poses to D-Wave

In the race to achieve quantum computing supremacy, a pure-play firm like D-Wave Quantum Inc. (NYSE: QBTS) must watch out for not only competitors of a similar size and scope but also for much

FEIM's Q3 Earnings Down Y/Y Due to Margin Pressure, Backlog Grows
FEIM's Q3 Earnings Down Y/Y Due to Margin Pressure, Backlog Grows

Shares of Frequency Electronics, Inc. FEIM have declined 11.4% since the company reported its earnings for the quarter ended Jan. 31, 2026, underperforming the S&P 500 index, which fell 2.1% over

NU's Post-Earnings Dip Despite Strong Results: A Buying Opportunity?
NU's Post-Earnings Dip Despite Strong Results: A Buying Opportunity?

Sometimes it helps to step back after results are out and let the market digest the numbers before concluding. Following its late-February earnings release, Nu Holdings NU saw its stock slide

Tredegar's Q4 Earnings Soar Y/Y on Aluminum Extrusions Strength
Tredegar's Q4 Earnings Soar Y/Y on Aluminum Extrusions Strength

Shares of Tredegar Corporation TG have underperformed the broader market following the release of its fourth-quarter results. The stock has declined 3.4% since the earnings announcement for the

Best Momentum Stocks on the Zacks Rank (CIEN, MU, CENX)
Best Momentum Stocks on the Zacks Rank (CIEN, MU, CENX)

There is always a bull market somewhere.

Despite shifting headlines and constantly evolving market narratives, certain stocks and sectors continue to benefit from prevailing economic regimes. In the

RGA Offers Upside on Strong Growth Prospects - Buy or Hold the Stock?
RGA Offers Upside on Strong Growth Prospects - Buy or Hold the Stock?

Reinsurance Group of America RGA is a leading global provider of traditional life and health reinsurance, as well as financial solutions, with operations across the United States, Latin America

KROS: Is the Discount Book Value a Value Trap?
KROS: Is the Discount Book Value a Value Trap?

Keros Therapeutics KROS posted a dramatic revenue jump in 2025, but the mix matters as much as the magnitude. The shares also trade at a steep discount to book value, creating the classic biotech

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Keros Therapeutics KROS enters 2026 with a clearer catalyst stack and a tighter operational focus. The near-term setup is led by rinvatercept, with study starts and regulatory interactions now

KROS Stock: What to Know About Rinvatercept in DMD
KROS Stock: What to Know About Rinvatercept in DMD

Keros Therapeutics, Inc. KROS is pushing its lead asset, rinvatercept, into neuromuscular disease with Duchenne muscular dystrophy at the front of the line. The company is positioning the program